Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and
correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a …

Background During early clinical development, prospective identification of a predictive
biomarker and validation of an assay method may not always be feasible. Dichotomizing a …

Objectives Patritumab is a fully human anti-human epidermal growth factor receptor 3
(HER3) antibody that blocks activation by its ligand, heregulin (HRG). Preclinical studies …

BACKGROUND• Many patients with advanced non–small cell lung cancer (NSCLC) initially
benefit from treatment with anti–epidermal growth factor receptor (EGFR) tyrosine kinase …

Abstract Background Seribantumab (MM‐121) is a fully human IgG2 monoclonal antibody
that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block heregulin …

Objectives Human epidermal growth factor receptor 3 (HER3) is a key dimerization partner
for HER family members and is associated with resistance to other HER family receptor …

Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor …

8051 Background: Heregulin induced activation of ErbB3 has been implicated as a
mechanism of resistance to many targeted therapies such as EGFR-TKIs in preclinical …

Background This phase 1 study evaluated the safety, tolerability, pharmacokinetics and
efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 …

ErbB3 is a critical activator of phosphoinositide 3-kinase (PI3K) signaling in epidermal
growth factor receptor (EGFR; ErbB1), ErbB2 [human epidermal growth factor receptor 2 …